410 related articles for article (PubMed ID: 34191622)
1. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.
Patel D; Busch R
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):524-532. PubMed ID: 34191622
[TBL] [Abstract][Full Text] [Related]
2. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
4. Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.
Hilleman DE; Wiggins BS; Bottorff MB
Adv Ther; 2020 Feb; 37(2):656-670. PubMed ID: 31919792
[TBL] [Abstract][Full Text] [Related]
5. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
6. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
Gutstein AS; Copple T
J Am Assoc Nurse Pract; 2017 Dec; 29(12):791-801. PubMed ID: 29280361
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease.
Barry AR; Dixon DL
Pharmacotherapy; 2021 Dec; 41(12):1056-1065. PubMed ID: 34431129
[TBL] [Abstract][Full Text] [Related]
9. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
Reddy KJ; Chowdhury S
Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
[TBL] [Abstract][Full Text] [Related]
10. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
11. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Brinton EA; Mason RP
Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
14. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
Bittner VA; Jacobson TA; Ballantyne CM; Guyton JR
J Clin Lipidol; 2020; 14(1):4-15. PubMed ID: 32192643
[TBL] [Abstract][Full Text] [Related]
15. Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis.
Quispe R; Alfaddagh A; Kazzi B; Zghyer F; Marvel FA; Blumenthal RS; Sharma G; Martin SS
Curr Atheroscler Rep; 2022 Jul; 24(7):571-581. PubMed ID: 35499805
[TBL] [Abstract][Full Text] [Related]
16. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
17. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson JR; True WS; Le V; Mason RP
Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
[TBL] [Abstract][Full Text] [Related]
18. Fish Oil and Cardiometabolic Diseases: Recent Updates and Controversies.
Tummala R; Ghosh RK; Jain V; Devanabanda AR; Bandyopadhyay D; Deedwania P; Aronow WS
Am J Med; 2019 Oct; 132(10):1153-1159. PubMed ID: 31077653
[TBL] [Abstract][Full Text] [Related]
19. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Mosca L; Navar AM; Wenger NK
J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
